Asia Pacific Immunohistochemistry Market Share, Size, Trends, Industry Analysis Report, By Product (Antibodies, Reagents, Equipment, Kits), By Application (Diagnostics, Research), By End-Use, By Country, And Segment Forecasts, 2024 - 2032
- Published Date:Jan-2024
- Pages: 119
- Format: PDF
- Report ID: PM4323
- Base Year: 2023
- Historical Data: 2019 – 2022
Report Outlook
Asia Pacific Immunohistochemistry Market size was valued at USD 492.16 million in 2023. The market is anticipated to grow from USD 532.81 million in 2024 to USD 1.1 Bn by 2032, exhibiting a CAGR of 8.9% during the forecast period.
Market Overview
The increasing prevalence of chronic conditions has resulted in a broader application of Immunohistochemistry (IHC) techniques in diagnostics. The steady rise in cancer incidence is expected to drive the market demand for effective diagnostic methods, with immunohistochemistry playing a significant role. This technique is crucial for determining oncogenesis and diagnosing cancer, distinguishing between malignant and benign tumors, and identifying different stages of the disease. It enables the use of polyclonal and monoclonal antibodies to detect specific antigens in tissues, providing valuable information about the presence of tumor antigens.
The field of conventional Immunohistochemistry (IHC) has undergone a revolution with the introduction of advanced techniques like multiplex IHC, computational pathology, and next-generation IHC. Multiplex IHC has the capability to amplify the amount of data obtained from a single or limited tissue sample, providing insights into cellular interactions. For instance, NeoGenomics' MultiOmyx is a multiplexing technique designed to analyze proteins and biomarkers within a single tumor section.
- For instance, in September 2023, Cell Signaling Technology (CST) launched SingalStar Multiplex IHC technology, enabling high-throughput IHC assays.
To Understand More About this Research: Request a Free Sample Report
Growth Drivers
Rise in healthcare spending
The global surge in healthcare spending is fueling the demand for the implementation of immunohistochemistry techniques in the healthcare sector. In 2020, the World Health Organization (WHO) reported a significant increase in global healthcare spending, reaching 11% of the global Gross Domestic Product (GDP) or USD 9 trillion. Furthermore, developing countries in Asia, including India, Indonesia, & Philippines, are ramping up their healthcare expenditure to enhance overall health services. The healthcare industry is transforming a fee-for-service model to a value-based model, where reimbursement is tied to treatment outcomes. There is increasing global pressure to reduce healthcare costs as they escalate more rapidly than the growth of economies.
Product launches
Major players in the market are unveiling new IHC reagents and antibodies tailored for the pharmaceutical and biotechnology industries. For instance, in March 2023, Aptamer Group plc introduced Optimer-Fc as a novel reagent designed for automated Immunohistochemistry (IHC) workflows. Additionally, through a collaboration with Bethyl Laboratories, Biocare Medical introduced a TIGIT IVD rabbit monoclonal antibody specifically for IHC applications. These strategic initiatives are contributing to the growth of the immunohistochemistry market.
Restraining Factors
Product substitutes
Immunohistochemistry faces a considerable number of direct product substitutes. The prevalence of traditional methods, flow cytometry, in-situ hybridization, & fluorescence detection is anticipated to have a negative impact. Nevertheless, the rapid technological advancements are poised to supplant conventional tools, mitigating the threat to some extent.
Report Segmentation
The market is primarily segmented based on product, application, end-use and region.
|
By Product |
By Application |
By End Use |
By Country |
|
|
|
|
To Understand the Scope of this Report: Speak to Analyst
By Product Analysis
Reagents segment is expected to witness the highest growth during the forecast period
The reagents segment is projected to grow at a CAGR during the projected period. These substances are crucial for ensuring consistent staining and delivering accurate results most efficiently. Manufacturers typically validate and optimize reagents, considering their specific use in a particular IHC procedure. The spectrum of reagents encompasses blocking sera and reagents, fixation reagents, chromogenic substrates, stabilizers, organic solvents, diluents, and proteolytic enzymes. The market offers a diverse array of reagents, each customized for specific steps within the IHC process.
The antibodies segment held the largest share. This substantial share is attributed to the extensive use of antibodies in disease diagnosis & drug testing. Antibodies are categorized into primary & secondary antibodies, forming a crucial foundation in various applications such as pathology, neuropathology, & hematopathology. Immunohistochemistry, involving antibody-antigen reactions for disease detection, is preferred over conventional staining procedures.
By Application Analysis
Diagnostic segment accounted for the largest market share in 2023
The diagnostic segment accounted for the largest market share in 2023. Immunohistochemistry serves as a widely utilized tool for diagnosing chronic conditions. It holds particular significance in cancer diagnosis by detecting specific tumor antigens in certain cancers. In the context of breast cancer diagnosis, Immunohistochemistry staining is applied to fresh or frozen tissue obtained during biopsy. This process aids in the identification of HER2 or hormone receptor proteins on the surface of cancer cells. The substantial applications of immunohistochemistry in diagnostics play a pivotal role in driving the growth of this segment.
The research segment is expected to grow at the fastest rate. IHC is a cornerstone for researchers in academia, pharmaceutical companies, & healthcare institutions aiming to advance knowledge across diverse fields such as oncology, neurology, immunology, & pathology. Robust investments by governments and academic institutions in medical research are contributing significantly to the growth of this segment.
By End-use Analysis
Hospitals segment registered the largest share of the market in 2023
Hospitals held the largest share. The evolving landscape of the healthcare industry, marked by continual advancements, has driven the demand for hospitals equipped with state-of-the-art facilities. Additionally, the increasing frequency of hospitalizations has substantially contributed to the robust growth of this segment. The escalating prevalence of chronic diseases like cancer, infectious diseases, & autoimmune diseases has fueled a heightened demand for hospitals, particularly for the detection of antigens in cancer diagnosis.
The research institutes segment will grow rapidly. It is primarily driven by the widespread adoption of immunohistochemistry techniques in drug testing. Research institutes actively engage with the consortia to combine resources, expertise, & data. These collaborative efforts contribute to the increased adoption of immunohistochemistry techniques for large-scale studies and clinical trials, thereby fostering growth in the market. For instance, in June 2023, where Lunaphore Technologies and Cell Signaling Technology partnered to provide researchers with a toolset for conducting spatial biology studies.
Regional Insights
Japan is expected to hold the largest share of the market throughout the forecast period. This is a rapidly aging population, heightened expectations for an improved quality of life, and government initiatives. Notably, Japan distinguishes itself from other countries by implementing country-wide cancer screening programs to address the escalating prevalence of cancer. This program extends cancer screening coverage to over 94% of the population, significantly contributing to regional growth.
China is expected to grow at the fastest pace. This growth is due to the increasing number of laboratories, & improvements in medical infrastructure. According to NCBI, one in ten individuals in China meets the criteria for obesity. This elevated prevalence of obesity has contributed to an increase in chronic conditions, including stroke, diabetes, & atrial fibrillation. The rising incidence of chronic diseases, coupled with a large target population and significant unmet clinical needs, is anticipated to provide robust support for the growth of the immunohistochemistry market.
Key Market Players & Competitive Insights
The market exhibits a notable level of innovation driven by swift technological advancements and increased automation in immunohistochemistry technologies. Immunohistochemistry (IHC) stands out as a cost-effective and relatively straightforward technique for investigating tissue micro-architecture and the molecular morphology of cells. This method plays a crucial role in comprehending the tissue micro-environment through the analysis of morphology, the localization of various molecules, and patterns of protein expression.
Some of the major players operating in the global market include:
- Abcam plc.
- Agilent Technologies, Inc.
- Amos Scientific PTY. LTD.
- Bio SB
- Bio-Rad Laboratories, Inc
- Cell Signaling Technology, Inc.
- Danaher Corporation
- Roche Ltd.
- HiMedia Laboratories
- IMGENEX INDIA Pvt. Ltd.
- Immuno-Biological Laboratories Co, Ltd.
- Kyowa Kirin Co., Ltd.
- Merck KGaA
- PathnSitu Biotechnologies Pvt Ltd
- PerkinElmer, Inc.
- Sino Biological, Inc.
- Thermo Fisher Scientific Inc.
Recent Developments in the Industry
- In September 2023, Cell Signaling Technology introduced the SingalStar Multiplex IHC technology, designed for the IHC assays.
- In January 2023, Agilent Technologies & Akoya Biosciences collaborated on commercializing workflow solutions for the multiplex assays. Additionally, the partnership aims to develop multi-plex IHC diagnostic solutions for tissue analysis.
Report Coverage
The Asia Pacific immunohistochemistry market report emphasizes on key regions across the globe to provide better understanding of the product to the users. Also, the report provides market insights into recent developments, market trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.
The report provides detailed analysis of the market while focusing on various key aspects such as competitive analysis, product, application, end use and their futuristic market growth opportunities.
Asia Pacific Immunohistochemistry Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 532.81 million |
|
Revenue forecast in 2032 |
USD 1053.08 million |
|
CAGR |
8.9% from 2024 – 2032 |
|
Base year |
2023 |
|
Historical data |
2019 – 2022 |
|
Forecast period |
2024 – 2032 |
|
Quantitative units |
Revenue in USD million and CAGR from 2024 to 2032 |
|
Segments covered |
|
|
Regional scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, region and segmentation. |
FAQ's
The Asia Pacific immunohistochemistry market size is expected to reach USD 1.1 billion by 2032
Key players in the market are Merck, Danaher, PerkinElmer, Bio SB, Agilent Technologies
key driving factors in asia pacific immunohistochemistry market are Rise in healthcare spending
Asia Pacific Immunohistochemistry Market exhibiting the CAGR of 8.9% during the forecast period.
The asia pacific immunohistochemistry market report covering key segments are product, application, end-use and Country.
